Adding Pembrolizumab May Up Response in Triple-Negative Breast Cancer
WEDNESDAY, Feb. 26, 2020 -- For patients with untreated stage II or III triple-negative breast cancer, pembrolizumab plus neoadjuvant chemotherapy, compared with placebo plus neoadjuvant chemotherapy, is associated with a significantly higher rate...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals